Results 231 to 240 of about 86,737 (312)

Prediction of cognitive outcome and progression to dementia using ω6‐PUFA/ω3‐PUFA ratio

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION The polyunsaturated fatty acids (PUFAs) omega‐6 (ω6) and omega‐3 (ω3) are linked to cognitive performance and Alzheimer's‐type dementia (DAT), but ω3‐PUFA supplementation offers limited benefits. We propose that the ω6‐PUFA/ω3‐PUFA ratio better explains cognitive decline and DAT risk.
Víctor Andrade   +19 more
wiley   +1 more source

Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease. [PDF]

open access: yesFront Pharmacol
Lindemann L   +15 more
europepmc   +1 more source

Mitochondrial NADK2‐dependent NADPH controls tau oligomer uptake in human neurons

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Reduced brain energy metabolism, mitochondria dysfunction, and extracellular tau oligomer buildup characterize Alzheimer's disease (AD), but how these phenomena cooperatively promote neurodegeneration is poorly understood. We now report that tau oligomers (TauOs) pathologically coordinate mitochondrial metabolism with increased ...
Evelyn Pardo   +10 more
wiley   +1 more source

Authorship and citation trends in dementia research: A path to equitable career development for scientists

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Women are increasingly entering the dementia research workforce, but they frequently fail to attain senior leadership positions in academia. Discrepancies in academic research outputs were investigated to guide equity‐focused policy recommendations.
Jayalakshmi Viswanathan   +18 more
wiley   +1 more source

Choroid plexus remodeling linked to impaired CSF‐mediated clearance and Alzheimer's disease progression

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Impaired cerebrospinal fluid (CSF) ‐mediated clearance has been implicated in Alzheimer's disease (AD), but how choroid plexus (ChP) remodeling relates to these processes in vivo remains incompletely understood. METHODS In a large ADNI cohort, we integrated structural magnetic resonance imaging (MRI), amyloid/tau positron emission
Haolin Yin   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy